Amanda J. Emmons

发表

In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action

Richard Graham Knowles, R. Sturton, Valerie S. Morrison, 2013, The Journal of Pharmacology and Experimental Therapeutics.

DMD048603 89..100

C. Beaumont, A. Harrell, R. Kempsford, 2012 .

Metabolism and Disposition of Vilanterol, a Long-Acting β2-Adrenoceptor Agonist for Inhalation Use in Humans

C. Beaumont, A. Harrell, R. Kempsford, 2013, Drug Metabolism and Disposition.

In vivo activity of an azole series of CCR2 antagonists.

Carl A. Brooks, V. Piercy, P. Gough, 2012, Bioorganic & medicinal chemistry letters.

CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.

J. Briand, C. Chung, N. Varga, 2011, Bioorganic & medicinal chemistry letters.

The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.

Roseanne Norris, D. Montanari, Ashley A. Barnes, 2009, Bioorganic & medicinal chemistry letters.

Development of an insect-cell-based assay for detection of kinase inhibition using NF-kappaB-inducing kinase as a paradigm.

D. Tew, S. Gul, F. Flett, 2009, The Biochemical journal.

The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.

R. Perciaccante, Valerie S. Morrison, P. Procopiou, 2011, Bioorganic & medicinal chemistry.

The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.

J. Willis, D. Montanari, Ashley A. Barnes, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.

I. McLay, Helen T Horsley, D. Coe, 2010, Journal of medicinal chemistry.

In Vitro Pharmacological Characterisation Of GW642444, A Novel Long Acting ²2-agonist (LABA) Using Human Recombinant ²1/2/3 Adrenoceptor CAMP Assays

R. Knowles, Amanda J Emmons, V. Barrett, 2010, ATS 2010.

Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors.

P. Grandi, A. Michon, P. Bamborough, 2015, Journal of medicinal chemistry.

Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.

Benjamin R Bellenie, J. Heer, N. Barton, 2009, Bioorganic & medicinal chemistry letters.

The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.

J. Willis, D. Montanari, Ashley A. Barnes, 2010, Bioorganic & medicinal chemistry letters.